Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1992-07-08
1994-10-25
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
A61K 4505
Patent
active
053587090
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to the use of a polypeptide having the activity of human interleukin 2 for the preparation of pharmaceutical compositions intended for the treatment of epithelial malignant tumours.
Interleukin 2 (IL.sub.2) which is a lymphokine produced by activated T lymphocytes possesses an immunomodulatory activity and an anti-tumour activity described for example by Fletcher, M et al. (Lymphokine Research 6 1987 47-57), which activities include in particular the ability to initiate the proliferation of the T lymphocyctes and the induction of the cytotoxicity of the NK (natural killer) cells and the LAK (lymphokine activated killer) cells. It has been observed that the administration of IL.sub.2 either on its own at a high dose or combined with LAK cells is able to induce the regression of certain cancers present in a mouse and in patients having metastatic cancers such as melanoma, cancer of the kidney, colorectal cancer or non-Hodgkin's lymphoma (Rosenberg, S A et al. N. Engl. J. Med. 1987 316 889-897).
Malignant epithelial tumours, or epitheliomas, which are tumours caused by a neoplasic proliferation of the epithelial cells or epidermis, or epidermoid mucous membranes, are histologically diagnosed, in particular in the upper aerodigestive tracts or in the thymus.
The epitheliomas of the upper aerodigestive tracts concern the various sites of the pharynx, amongst which the nasopharynx which represents a relatively frequent localization with different histological sub-types, most often of lymphoepithelial type characterized by an undifferentiated epithelioma infiltrated by lymphocytes.
The most important treatment of epitheliomas is radiotherapy, generally preceded by polychemotherapy or combined with the latter. The prognosis, variable according to the development of the epithelioma, is unfavourable in as much as a large percentage of patients treated develop metastases afterwards. Thus a study involving 49 patients suffering from carcinomas of the nasopharynx and treated by radio-therapy, either on its own or preceded by chemotherapy, describes an average survival rate of 42% after 5 years (Stein, M et al. J. Surg. Oncol. 1988 37 (2) 84-88). In spite of a prognosis which seems better when lymphoepitheliomas are concerned, a low survival rate of only 13% is observed after 5 years in a study involving 150 patients suffering from nasopharyngeal carcinoma, most frequently of lymphoepithelial type, although a complete remission rate of about 65% was described after radiotherapy preceded or not preceded by chemotherapy (Koppibar, S Bet al. J. Surg. Oncol. 1988 39 (3) 179-182). The absence of an effective treatment is also recognized, notably in 29 children all suffering from lymphoepitheliomas of the nasopharynx, amongst which more than 50% developed secondary metastases within 2 years once the radiotherapy had stopped (Pao, W J et al. In. J. Radiat. Oncol. Biol. Phys 1989 17 (2) 299-305).
Malignant thymomas which are tumours of the thymus caused by a neoplastic proliferation of the epithelial cells of the thymus include mainly invasive malignant thymomas without atypia, amongst which there can possibly be singled out the lymphoepithelial or lymphocytary sub-type according to the cell population which accompanies them, and the atypical carcinomas of the thymus.
In contrast to benign encapsulated thymomas for which suitable treatments exist such as surgery, radiotherapy, alone or combined, malignant thymomas, in particular invasive malignant thymomas without atypia, are not very sensitive to conventional treatments. Furthermore, the frequency with which they appear is increasing (23 to 66% of all thymomas).
Thus invasive malignant thymomas treated either by surgery, or by radiotherapy as the first treatment, followed optionally by chemotherapy, have an unfavourable prognosis: up to 30% of the patients secondarily develop metastases. The results described for patients suffering from lymphoepithelial thymomas (Arriagada, R et al. Eur J Cancer Clin Oncol 20 (No. 1) 69-74 1984) or for patients su
REFERENCES:
Berthaud et al, The Lancet, vol. 335 (8705) Jun. 30, 1990, p. 1590.
Hsu et al, Biol. Abst. 89(6) #60857, 15 Mar. 1990, p. AB-623.
Kolitz et al, J. Biol. Resp. Mod., vol. 6, No. 4. 1987 Raven Press, pp. 412-429.
Ju et al., J. Biol. Chem. vol. 262, No. 12, Apr. 25, 1987, pp. 5723-5731.
Taniguchi et al, Nature, vol. 302, Mar. 24, 1983 pp. 305-310.
Brandely Maud
Tursz Thomas
Roussel Uclaf
Sayala C.
Wityshyn Michael G.
LandOfFree
Antitumoral composition based on polypeptides having human inter does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitumoral composition based on polypeptides having human inter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumoral composition based on polypeptides having human inter will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-133599